Genetic tests for complex diseases and drug response that assist healthcare providers in determining the most efficacious and safe treatment for their patients as well as, in some cases, propensity for developing a given disease.
Progenika’s mission is to improve healthcare through the development and commercialization of diagnostic and prognostic products to personalize the treatment of genetically complex diseases.
is a microarray for the diagnosis of Familial Hypercholesterolemia and was released in Europe in June 2004 to become the first CE-marked DNA microarray for routine clinical diagnosis.
was developed to improve the safety of transfusions by genetically characterizing blood group antigens of both donors and recipients.
, is a tool for predicting drug response in a broad array of metabolism pathways to improve safety and effectiveness of therapeutic strategies.
With the collaboration of:
